Page 147 - MI-2-4

Microbes & Immunity Glioblastoma therapy: Immunotherapy and inhibitors

treatment modalities besides surgery. J Cancer. 19. Brandao M, Simon T, Critchley G, Giamas G. Astrocytes,
2019;10(20):4793-4806. the rising stars of the glioblastoma microenvironment. Glia.
2018;67(5):779-790.
doi: 10.7150/jca.32475
doi: 10.1002/glia.23520
8. Louis DN, Perry A, Reifenberger G, et al. The 2016
World Health Organization classification of tumors of the 20. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic
central nervous system: A summary. Acta Neuropathol. glioma: Genetics, biology, and paths to treatment. Genes
2016;131(6):803-820. Dev. 2007;21(21):2683-2710.
doi: 10.1007/s00401-016-1545-1 doi: 10.1101/gad.1596707
9. Ohgaki H, Kleihues P. The definition of primary and secondary 21. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN,
glioblastoma. Clin Cancer Res. 2013;19(4):764-772. Canoll P. Transplanted glioma cells migrate and proliferate
on host brain vasculature: A dynamic analysis. Glia.
doi: 10.1158/1078-0432.ccr-12-3002 2006;53(8):799-808.
10. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: doi: 10.1002/glia.20334
From concept to clinical diagnosis. Neuro Oncol.
1999;1(1):44-51. 22. De Gooijer MC, Guillén Navarro M, Bernards R, Wurdinger T,
van Tellingen O. An experimenter’s guide to glioblastoma
doi: 10.1093/neuonc/1.1.44 invasion pathways. Trends Mol Med. 2018;24(9):763-780.
11. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 doi: 10.1016/j.molmed.2018.07.003
mutations as molecular signature and predictive factor of
secondary glioblastomas. Clin Cancer Res. 2009;15(19): 23. Coniglio SJ, Eugenin E, Dobrenis K, et al. Microglial
6002-6007. stimulation of glioblastoma invasion involves epidermal
growth factor receptor (EGFR) and colony stimulating factor
doi: 10.1158/1078-0432.ccr-09-0715 1 receptor (CSF-1R) signaling. Mol Med. 2012;18(3):519-527.
12. Amankulor NM, Kim Y, Arora S, et al. Mutant IDH1 doi: 10.2119/molmed.2011.00217
regulates the tumor-associated immune system in gliomas.
Genes Dev. 2017;31(8):774-786. 24. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma:
An overview of proliferation and invasion. Neuro Oncol.
doi: 10.1101/gad.294991.116 2014;16(12):1575-1584.
13. Waitkus MS, Yan H. Targeting isocitrate dehydrogenase doi: 10.1093/neuonc/nou147
mutations in cancer: Emerging evidence and diverging 25. Mrugala MM. Advances and challenges in the treatment
strategies. Clin Cancer Res. 2021;27(2):383-388. of glioblastoma: A clinician’s perspective. Discov Med.
doi: 10.1158/1078-0432.ccr-20-1827 2013;15(83):221-230.
14. Nakada M, Kita D, Watanabe T, et al. Aberrant signaling 26. Ohka F, Natsume A, Wakabayashi T. Current trends in
pathways in glioma. Cancers (Basel). 2011;3(3):3242-3278. targeted therapies for glioblastoma multiforme. Neurol Res
Int. 2012;2012:878425.
doi: 10.3390/cancers3033242
doi: 10.1155/2012/878425
15. McLendon R, Friedman A, Bigner D. Comprehensive
genomic characterization defines human glioblastoma genes 27. Scott J, Tsai YY, Chinnaiyan P, Yu HHM. Effectiveness of
and core pathways. Nature. 2008;455(7216):1061-1068. radiotherapy for elderly patients with glioblastoma. Int J
Radiat Oncol Biol Phys. 2011;81(1):206-210.
doi: 10.1038/nature07385
doi: 10.1016/j.ijrobp.2010.04.033
16. Nagane M. Neuro-oncology: Continuing multidisciplinary
progress. Lancet Neurol. 2011;10(1):18-20. 28. Nabors LB, Portnow J, Ammirati M, et al. Central nervous
system cancers, version 1.2015. J Natl Compr Canc Netw.
doi: 10.1016/s1474-4422(10)70302-1 2015;13(10):1191-1202.
17. Stupp R, Weller M. 2010: Neuro-oncology is moving! Curr doi: 10.6004/jnccn.2015.0148
Opin Neurol. 2010;23(6):553-555.
29. Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and
doi: 10.1097/wco.0b013e3283407eed gefitinib interchangeable, opposite or complementary
18. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, for non-small cell lung cancer treatment? Biological,
Wen PY, Olson JJ. Exciting new advances in neuro-oncology: pharmacological and clinical aspects. Crit Rev Oncol
The avenue to a cure for malignant glioma. CA Cancer J Clin. Hematol. 2014;89(2):300-313.
2010;60(3):166-193. doi: 10.1016/j.critrevonc.2013.08.003
doi: 10.3322/caac.20069 30. Iacob G, Dinca EB. Current data and strategy in glioblastoma

Volume 2 Issue 4 (2025) 139 doi: 10.36922/mi.5075